Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nasus Pharma Ltd. ( (NSRX) ) has issued an announcement.
On February 10, 2026, Nasus Pharma Ltd. signed a definitive securities purchase agreement with institutional and accredited investors for a $15 million private placement of ordinary shares and accompanying warrants, priced at a premium to its last NYSE American closing price. The transaction, expected to close around February 12, 2026, includes 2,695,425 shares and matching warrants with a $6.53 exercise price, and also involves registration rights and a 6% fee to placement agents Citizens Capital Markets and Laidlaw & Company.
Nasus plans to deploy the new capital, alongside existing cash and investments, to advance the pivotal clinical development of NS002 for anaphylaxis, launch first-in-human studies for additional pipeline products, and fund working capital and general corporate needs. Participation by both new and existing investors, including board members, underscores investor confidence and provides critical funding to progress its needle-free intranasal platform toward key clinical milestones, potentially strengthening its competitive position in acute care therapeutics.
The most recent analyst rating on (NSRX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing innovative intranasal powder therapies for acute medical conditions in community settings. Its lead candidate, NS002, is an intranasal epinephrine powder being developed as a needle-free alternative to epinephrine autoinjectors for anaphylaxis, leveraging its proprietary powder-based intranasal technology for rapid drug delivery.
Average Trading Volume: 6,129
Technical Sentiment Signal: Strong Sell
See more data about NSRX stock on TipRanks’ Stock Analysis page.